Black Rock Inc. Avalo Therapeutics, Inc. Transaction History

Black Rock Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$3.15 - $808.8 $3.92 Million - $1.01 Billion	-1,243,976 Closed	0 $0
Q2 2022 Aug 12, 2022	SELL	$3.0 - $10.45 $7.57 Million - $26.4 Million	-2,521,922 Reduced 66.97%	1,243,976 $622,000
Q1 2022 May 12, 2022	SELL	$7.57 - $21.72 $273,367 - $784,352	-36,112 Reduced 0.95%	3,765,898 $2.73 Million
Q4 2021 Feb 10, 2022	BUY	$19.68 - $28.68 $1.67 Million - $2.44 Million	85,067 Added 2.29%	3,802,010 $6.46 Million
Q3 2021 Nov 09, 2021	BUY	$26.16 - $40.68 $97.2 Million - $151 Million	3,716,943 New	3,716,943 $8.1 Million

34.6K

Ticker AVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 9,414,100
Market Cap $91.1M
Description
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the tr...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.